Search Result

Results for "

diarrheal

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Autophagy (2) Biochemical Assay Reagents (1) Calcium Channel (2) CFTR (1) Endogenous Metabolite (1) Opioid Receptor (2) Reference Standards (1) SARS-CoV (1) Sodium Channel (2)
By Research Areas:	Cancer (4) Cardiovascular Disease (2) Infection (5) Metabolic Disease (4) Neurological Disease (4)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0418A

Loperamide hydrochloride Maximum Cited Publications 12 Publications Verification R-18553 hydrochloride	Opioid Receptor Autophagy	Neurological Disease Metabolic Disease Cancer
Loperamide (hydrochloride) (R-18553 (hydrochloride)) is an opioid receptor agonist . Loperamide hydrochloride is a selective and competitive human intestinal carboxylesterases (hiCE) inhibitor. Loperamide hydrochloride has anti-diarrheal effect .

HY-18337

IOWH-032 4 Publications Verification	CFTR SARS-CoV	Infection Metabolic Disease
IOWH-032 is a a synthetic anti-secretory molecule, is a potent CFTR inhibitor with an IC₅₀ value of 8 μM. IOWH-032 also is a anti-diarrheal agent .

HY-B0418AR

Loperamide hydrochloride (Standard) 5+ Cited Publications R-18553 hydrochloride (Standard)	Reference Standards Opioid Receptor Autophagy	Neurological Disease Metabolic Disease Cancer
Loperamide (hydrochloride) (Standard) is the analytical standard of Loperamide (hydrochloride). This product is intended for research and analytical applications. Loperamide (hydrochloride) (R-18553 (hydrochloride)) is an opioid receptor agonist . Loperamide hydrochloride is a selective and competitive human intestinal carboxylesterases (hiCE) inhibitor. Loperamide hydrochloride has anti-diarrheal effect .

HY-105084A

Lubeluzole dihydrochloride	Sodium Channel Calcium Channel	Cardiovascular Disease Infection Neurological Disease Cancer
Lubeluzole dihydrochloride is the dihydrochloride salt of Lubeluzole (HY-105084). Lubeluzole dihydrochloride is the S-isomer of benzothiazole derivative. Lubeluzole dihydrochloride can inhibit glutamate release, glutamate-activated NO synthesis and block voltage-gated Sodium Channel and Calcium Channel. Lubeluzole dihydrochloride exhibits anti-ischemic and neuroprotective effects. Lubeluzole dihydrochloride also shows anti-bacterial and anti-diarrheal potential. Lubeluzole dihydrochloride can inhibit cardiac sodium channel and prolong cardiac action potential. Lubeluzole dihydrochloride can inhibit cancer cells proliferation and invasion and shows chemosensitizing effect. Lubeluzole dihydrochloride can be used for the researches of cancer, infection, neurological and cardiovascular disease such as stroke, infectious diarrhea and ovarian .

HY-130530

AP-C5	Biochemical Assay Reagents	Metabolic Disease
AP-C5 displays selective inhibition of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC₅₀ of 7.2, which can be used for the research of diarrheal disease . AP-C5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-105084

Lubeluzole	Sodium Channel Calcium Channel	Infection Cardiovascular Disease Neurological Disease Cancer
Lubeluzole is the S-isomer of benzothiazole derivative. Lubeluzole can inhibit glutamate release, glutamate-activated NO synthesis and block voltage-gated Sodium Channel and Calcium Channel. Lubeluzole exhibits anti-ischemic and neuroprotective effects. Lubeluzole also shows anti-bacterial and anti-diarrheal potential. Lubeluzole can inhibit cardiac sodium channel and prolong cardiac action potential. Lubeluzole can inhibit cancer cells proliferation and invasion and shows chemosensitizing effect. Lubeluzole can be used for the researches of cancer, infection, neurological and cardiovascular disease such as stroke, infectious diarrhea and ovarian .

HY-165650

C16 Ganglioside GM1 (d18:1/16:0) C16-GM1; N-Hexadecaoyl (13,13,14,14,15,15,16,16,16)-moosialogaglioside GM1	Others	Infection
C16 Ganglioside GM1 (d18:1/16:0) (C16-GM1) is a member of the ganglioside family containing saturated C16:0 acyl chains. C16 Ganglioside GM1 (d18:1/16:0) serves as a functional receptor for Cholera toxin (HY-P1446) B subunit, while showing reduced efficiency in both transcytosis and retrograde pathways. C16 Ganglioside GM1 (d18:1/16:0) can be used for diarrheal diseases research .

HY-165650A

C16 Ganglioside GM1 (d18:1/16:0) ammonium C16-GM1 ammonium; N-Hexadecaoyl (13,13,14,14,15,15,16,16,16)-moosialogaglioside GM1 ammonium	Endogenous Metabolite	Infection
C16 Ganglioside GM1 (d18:1/16:0) (C16-GM1) ammonium is a member of the ganglioside family containing saturated C16:0 acyl chains. C16 Ganglioside GM1 (d18:1/16:0) ammonium serves as a functional receptor for Cholera toxin (HY-P1446) B subunit, while showing reduced efficiency in both transcytosis and retrograde pathways. C16 Ganglioside GM1 (d18:1/16:0) ammonium can be used for diarrheal diseases research .

Cat. No.	Product Name		Classification

HY-130530

AP-C5		Alkynes
AP-C5 displays selective inhibition of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC₅₀ of 7.2, which can be used for the research of diarrheal disease . AP-C5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.